Based on the finding of largeclinical trials and meta-analyses, NT-proBNP represents an effective outcomeparameter for SGLT2 inhibition in heart failure, but potential clinical effectsof SGLT2-inhibitors seem to be underestimated. Here, NPPB is linked to heart failure.